Abstract
The first vaccine that shows significant potential in providing broad coverage against serogroup B meningococcal disease has recently been approved. Because of its newness, potential adverse events need to be reported. Here we report a case of urticarial vasculitis, a rare disease in children, in probable relationship with the novel vaccine.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2hRrBXa
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου